MedGenome brings easy-to-do genetic screening to India

Bengaluru-based MedGenome Labs has launched its directto-consumer category under the brand name Genessense for consumers in India. Under Genessense, MedGenome will offer specialised, evidence-based genetic screening tests that can be ordered online through the Genessense website or via e-commerce platforms in future. The company that operates one of the biggest genomic testing labs with highly specialised tests in South Asia will initially offer two tests - namely Kardiogen and Curegen under the umbrella of personal genomics. Kardiogen will be India’s first Polygenic Risk Score based predictive test for Coronary Artery Disease (CAD) with a proven specificity of 90 per cent for the Indian population. Kardiogen will help one assess the risk of developing Coronary Artery Diseases (CAD) or heart attacks based on their genetic makeup while Curegen is a genome-based drug response test that will outline an individual’s reaction to different drugs or medications. The test will help consumers in avoiding adverse drug reactions and improving response to medications.